Eagle Pharmaceuticals (EGRX) Downgraded to Hold at Zacks Investment Research

Eagle Pharmaceuticals (NASDAQ:EGRX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

A number of other research firms have also recently commented on EGRX. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 2nd. ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Royal Bank of Canada restated an “outperform” rating and set a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. Piper Jaffray Companies reiterated a “buy” rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. Finally, Mizuho reiterated a “sell” rating and issued a $37.00 price objective on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Eagle Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $62.33.

Eagle Pharmaceuticals (NASDAQ:EGRX) traded up $0.49 during trading hours on Tuesday, reaching $58.84. The company’s stock had a trading volume of 154,253 shares, compared to its average volume of 200,550. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26. Eagle Pharmaceuticals has a one year low of $45.05 and a one year high of $97.15. The firm has a market capitalization of $870.68, a PE ratio of 9.48 and a beta of 1.24.

Several hedge funds and other institutional investors have recently made changes to their positions in EGRX. Janus Henderson Group PLC acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at $144,384,000. Thrivent Financial For Lutherans raised its stake in shares of Eagle Pharmaceuticals by 17,917.8% in the second quarter. Thrivent Financial For Lutherans now owns 828,820 shares of the specialty pharmaceutical company’s stock valued at $65,386,000 after acquiring an additional 824,220 shares in the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in shares of Eagle Pharmaceuticals by 271.6% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 386,132 shares of the specialty pharmaceutical company’s stock valued at $23,028,000 after acquiring an additional 282,225 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Eagle Pharmaceuticals by 1,045.7% in the second quarter. Lazard Asset Management LLC now owns 278,108 shares of the specialty pharmaceutical company’s stock valued at $21,939,000 after acquiring an additional 253,833 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Eagle Pharmaceuticals by 808.7% in the third quarter. Prudential Financial Inc. now owns 222,072 shares of the specialty pharmaceutical company’s stock valued at $13,244,000 after acquiring an additional 197,634 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Eagle Pharmaceuticals (EGRX) Downgraded to Hold at Zacks Investment Research” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/09/eagle-pharmaceuticals-egrx-downgraded-to-hold-at-zacks-investment-research.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Eagle Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eagle Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit